ImmunityBio (IBRX) News Today $2.81 -0.06 (-2.09%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.82 +0.02 (+0.53%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period ImmunityBio's (IBRX) "Buy" Rating Reaffirmed at D. Boral CapitalJuly 11 at 2:11 AM | americanbankingnews.comImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study UpdateJuly 9 at 12:16 PM | tipranks.comImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral CapitalJuly 8, 2025 | marketbeat.comUK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituJuly 7, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's What HappenedJuly 7, 2025 | marketbeat.comBullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA AuthorizationJuly 7, 2025 | msn.comImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial SuccessJuly 2, 2025 | msn.comImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVAJune 24, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Shares Down 5.1% - Here's WhyJune 23, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.9% - Here's WhyJune 17, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Down - Here's WhyJune 13, 2025 | marketbeat.comImmunityBio: Lymphopenia Opportunity Could Provoke Short SqueezeJune 12, 2025 | seekingalpha.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $670,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)June 12, 2025 | marketbeat.comImmunityBio (IBRX) Jumps 18% on Anktiva Access ExpansionJune 10, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?June 9, 2025 | marketbeat.com15 Stocks That Stole The Show Last WeekJune 8, 2025 | insidermonkey.comMillennium Management LLC Reduces Position in ImmunityBio, Inc. (NASDAQ:IBRX)June 8, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 6.3% - Should You Buy?June 4, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)June 4, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's WhyJune 3, 2025 | marketbeat.comImmunityBio receives FDA Expanded Access authorization for Cancer BioShieldJune 3, 2025 | finance.yahoo.comASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic CancerJune 3, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral CapitalJune 3, 2025 | marketbeat.comImmunityBio gets FDA expanded access authorization to treat lymphopenia with AnktivaJune 2, 2025 | msn.comImmunityBio Sees Unusually Large Options Volume (NASDAQ:IBRX)June 2, 2025 | marketbeat.comDeutsche Bank AG Reduces Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)June 1, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading 6.3% Higher - Time to Buy?May 30, 2025 | marketbeat.comWhy ImmunityBio, Inc. (IBRX) Surged On ThursdayMay 30, 2025 | msn.comImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral CapitalMay 29, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Time to Buy?May 28, 2025 | marketbeat.comWoodline Partners LP Buys 3,002,622 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)May 25, 2025 | marketbeat.com10 Firms Drenched in Red TodayMay 23, 2025 | insidermonkey.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by Rafferty Asset Management LLCMay 23, 2025 | marketbeat.comPiper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PTMay 22, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Rating Increased to Overweight at Piper SandlerMay 22, 2025 | marketbeat.comJim Cramer’s Recent Thoughts on These 15 StocksMay 21, 2025 | insidermonkey.comJim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever”May 20, 2025 | msn.comImmunityBio upgraded to Overweight at Piper Sandler on Anktiva successMay 20, 2025 | msn.comWhy ImmunityBio, Inc. (IBRX) Surged Last WeekMay 20, 2025 | msn.comTang Capital Management LLC Makes New $7.20 Million Investment in ImmunityBio, Inc. (NASDAQ:IBRX)May 20, 2025 | marketbeat.comImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The UpsideMay 18, 2025 | msn.comEarnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00May 14, 2025 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Up 15.1% - Still a Buy?May 14, 2025 | marketbeat.comImmunityBio's (IBRX) "Buy" Rating Reaffirmed at HC WainwrightMay 14, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)May 14, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Issues Earnings ResultsMay 14, 2025 | marketbeat.comWhy These 10 Stocks Soared by Double Digits TodayMay 14, 2025 | insidermonkey.comWhy ImmunityBio, Inc. (IBRX) Soared TodayMay 13, 2025 | msn.comImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-codeMay 12, 2025 | businesswire.comFirst Trust Advisors LP Has $428,000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)May 12, 2025 | marketbeat.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.351.00▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼84▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BPMC News BBIO News VRNA News ROIV News ELAN News RVMD News LEGN News GRFS News TGTX News NUVL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
